Anticoagulant drugs with or without proton pump inhibitor and colorectal cancer risk: a population-based, case–control study

Table 3 Relationship between DOAC and incidence of CRC

Variables	CRC (N = 10,481)	Non-CRC^a (N = 41,924)	Crude OR (95%CI)	Adjusted OR^b (95%CI)
DOAC
Apixaban	7(0.07)	24(0.06)	1.173(0.505–2.722)	0.746(0.309–1.800)
Dabigatran	29(0.28)	77(0.18)	1.514(0.987–2.322)	1.250(0.802–1.948)
Edoxaban	4(0.04)	8(0.02)	2.007(0.604–6.668)	2.056(0.616–6.868)
Rivaroxaban	57(0.54)	146(0.35)	1.570(1.154–2.135)**	1.261(0.916–1.736)
Non-drug user	10,384(99.07)	41,669(99.39)	ref	ref

^aModel was adjusted only for matching variables (age, gender, and year of index date), two groups present at 1:4 ratio
^bModel was adjusted for the following variables: age, gender, and year of index date; comorbidities and risk factors, including smoking, alcohol usage, hypertension, diabetes mellitus, cardiovascular disease, stroke, inflammatory bowel disease, GI bleeding
*p < 0.05, **p < 0.01, ***p < 0.001

ISSN: 1471-230X